



**GIG**  
CYMRU  
**NHS**  
WALES

Bwrdd Iechyd Prifysgol  
Bae Abertawe  
Swansea Bay University  
Health Board

Cadeirydd Dros Dro/ Interim Chair: **Emma Woollett**  
Prif Weithredwr/Chief Executive: **Tracy Myhill**

**gofalu am ein gilydd, cydweithio, gwella bob amser**  
**caring for each other, working together, always improving**

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 25<sup>th</sup> September 2019  
Ein Cyf / Our Ref: 19-I-003

☎ 01639 648363  
✉ FOIA.Requests@wales.nhs.uk

[Redacted]

Corporate Services  
Headquarters  
1 Talbot Gateway  
Baglan  
Port Talbot, SA12 7BR

[Redacted]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 6<sup>th</sup> September 2019. Your request sought information relating to cancer.

**1. How many melanoma patients undergoing treatment are BRAF+ ?**

The number of patients currently being treated is not held centrally. Information can only be provided for patients at point of presentation but not at any other point in their pathway. To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

**1a In the past 3 months, how many melanoma patients were treated with the following:**

<b>Bevacizumab</b>	Nil
<b>Cobimetinib</b>	Nil
<b>Dabrafenib</b>	<5
<b>Dabrafenib AND trametinib</b>	15
<b>Dacarbazine</b>	Nil
<b>Encorafenib AND binimetinib</b>	6
<b>Ipilimumab</b>	Nil
<b>Ipilimumab AND Nivolumab</b>	Nil
<b>Nivolumab</b>	Nil
<b>Pembrolizumab</b>	Nil
<b>Trametinib</b>	Nil



**Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR**

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe  
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

<b>Vemurafenib</b>	<5
<b>Vemurafenib AND Cobimetinib</b>	Nil
<b>Other active systemic anti-cancer therapy</b>	Nil
<b>Palliative care</b>	not held centrally

1b. **In the past 3 months how many patients were seen who had stage III resectable melanoma**

The number of patients currently being treated is not held centrally. Information can only be provided for patients at point of presentation but not at any other point in their pathway. To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

1c. **Of all stage III patients seen, how many received a complete resection**

The number of patients currently being treated is not held centrally. Information can only be provided for patients at point of presentation but not at any other point in their pathway. To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

1d. **Of all stage III patients seen, how many were stage III a?**

The number of patients currently being treated is not held centrally. Information can only be provided for patients at point of presentation but not at any other point in their pathway. To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

2. **In the past 3 months, how many Squamous Cell Non-small cell lung cancer (SqNSCLC) patients were treated with:**

<b>Afatinib</b>	Nil
<b>Atezolizumab monotherapy</b>	<5
<b>Bevacizumab</b>	Nil
<b>Docetaxel monotherapy</b>	<5
<b>Durvalumab</b>	Nil
<b>Erlotinib</b>	Nil
<b>Gemcitabine</b>	Nil
<b>Necitumumab</b>	Nil
<b>Nivolumab</b>	Nil
<b>Paclitaxel</b>	Nil



<b>Pembrolizumab monotherapy</b>	7	
<b>Pembrolizumab chemo in combination</b>	Nil	
<b>Pemetrexed</b>	Nil	
<b>Ramucirumab</b>	Nil	
<b>Vinorelbine and cisplatin / carboplatin</b>	10	
<b>Other active systemic anti-cancer therapy [please state]</b>	Nil	
<b>Palliative care only</b>		not held centrally

3. **In the past 3 months, how many Non Squamous Cell Non-small cell lung cancer (Non SqNSCLC) patients were treated with:**

<b>Afatinib</b>	<5	
<b>Alectinib</b>	Nil	
<b>Atezolizumab mono</b>	<5	
<b>Atezolizumab+bevacizumab+ carboplatin + paclitaxel</b>		
<b>Bevacizumab</b>	Nil	
<b>Brigatinib</b>	Nil	
<b>Ceritinib</b>	<5	
<b>Crizotinib</b>	<5	
<b>Dacomitinib</b>	Nil	
<b>Docetaxel monotherapy</b>	Nil	
<b>Erlotinib</b>	<5	
<b>Gefitinib</b>	6	
<b>Nintedanib with docetaxel</b>	Nil	
<b>Nivolumab</b>	Nil	
<b>Osimertinib</b>	<5	
<b>Paclitaxel</b>	Nil	
<b>Pembrolizumab monotherapy</b>	13	
<b>Pembrolizumab chemo in combination</b>	<5	
<b>Pemetrexed with carboplatin</b>	<5	
<b>Pemetrexed with cisplatin</b>	Nil	
<b>Ramucirumab</b>	Nil	
<b>Other active systemic anti-cancer therapy [please state]</b>		
<b>Gemcitabine/Docetaxel</b>	<5	
<b>Pemetrexed single agent</b>	<5	
<b>Vinorelbine/Carboplatin</b>	<5	
<b>Vinorelbine/Cisplatin</b>	<5	
<b>Palliative care only</b>		not held centrally

4. **In the past 3 months, how many Urothelial cancer patients were treated with;**

<b>Atezolizumab</b>	<5	
<b>Carboplatin in combination with another agent</b>	<5	
<b>Carboplatin single agent</b>	Nil	
<b>Cisplatin in combination with another agent</b>	<5	
<b>Cisplatin single agent</b>	Nil	
<b>Nivolumab</b>	Nil	
<b>Pembrolizumab</b>	<5	
<b>Any other chemo regimen without cisplatin or carboplatin</b>	Nil	
<b>Other active systemic anti-cancer therapy [please state]</b>	Nil	
<b>Palliative care only</b>		not held centrally



Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2<sup>nd</sup> Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



Pam Wenger  
**Director of Corporate Governance**

